Navigation Links
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
Date:8/14/2014

n stock to LPC over the 30-month term of the agreement. The funds, in part, will serve to advance research and development activities for the Company's ophthalmological pre-clinical drug pipeline.
  • Announced the Initiation of a Phase 2 Keloid Study: The Company announced in April 2014 that the first patient in the Company's Phase 2a study (RXI-109-1401) was enrolled for the prevention of keloid recurrence. In this study, patients with two keloids of similar size and location are selected for keloidectomy. After this procedure, the lesions are closed and one is treated with RXI-109, and the other is treated with placebo. Patients will be followed for several months after the end of treatment.
  • Positive Results with RXI-109 in the Eyes of Cynomolgus Monkeys as Part of a Dose-Range Finding Study: The Company announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection of RXI-109 in the eyes of cynomolgus monkeys as part of a dose-range finding study. Intravitreal administration of RXI-109 resulted in a reduction of CTGF protein levels in a dose-dependent manner in the retina, as well as in cornea tissue. IND-supporting toxicity testing of RXI-109 in the eye is slated to begin soon.
  • Granted U.S. Notice of Allowance Covering Self-Delivering (sd-rxRNA®) Technology Platform: The Company received a Notice of Allowance from the United States Patent and Trademark Office in May 2014 on a patent covering our novel, self-delivering RNAi platform (sd-rxRNA). The patent titled "Reduced Size Self-Delivering RNAi Compounds" broadly covers both the composition and methods of use of our self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029.
  • Appointment of Peter Campochiaro, M.D. to the Company's Scientific Advisory Board: Dr. Peter Campochiaro joined
    '/>"/>

  • SOURCE RXi Pharmaceuticals Corporation
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Israel Biomedical Sensors Market - Growth, ... The Israel Biomedical Sensors market is ... of 3.73% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
    (Date:8/31/2015)... 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapies primarily in the areas ... 30-day review period following the filing of the ... with the U.S. Food and Drug Administration (FDA) ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
    (Date:8/31/2015)... 31, 2015 LabStyle Innovations Corp. (OTCQB: ... today announced it recently closed a round of ... used to support the global rollout and initial ... cloud-based, diabetes management solution that includes novel software ... glucose monitoring device, and for working capital purposes. ...
    (Date:8/31/2015)... Redwood City, CA (PRWEB) , ... August 31, 2015 , ... ... Ablation System. Minerva is the first commercially available new FDA approved system ... high treatment Success rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, ...
    Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
    ... EntreMed, Inc.,(Nasdaq: ENMD ), a ... of cancer and inflammatory diseases, today,announced the ... or 2-,methoxyestradiol) in rheumatoid arthritis (RA). The ... Dr. Ernest Brahn, Professor of,Medicine, Rheumatology Program ...
    ... and LOD, Israel, November 3 Simbionix,USA Corporation ... for training medical professionals, today announced that William,E. ... Marketing Director on,November 10th, 2008. Gary Zamler, Simbionix ... has enjoyed double digit revenue growth in,both our ...
    ... elusive metal-hydroxide compound in sufficient and rapidly produced ... inks that could boost semiconductor capabilities for large-area ... of possibly the first heterometallic gallium-indium hydroxide nanocluster ... in place of nitrosobenzene. , The substitute was ...
    Cached Biology Technology:Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models 2Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models 3Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models 4William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionix's Strategic Expansion in the US Market 2New nanocluster to boost thin films for semiconductors 2
    (Date:8/5/2015)... 5, 2015 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... facial recognition is forecast to reach US$ 2,671.8 Mn ... for surveillance systems by civil and government agencies. This ... and terrorist activities across the globe that would elevate ...
    (Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
    (Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
    Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
    ... would happen if a fast-food restaurant reduces the calories ... decreasing the portion size of French fries? Would children ... beverage? Researchers at Cornell University, Dr. Brian Wansink and ... McDonald,s restaurants to answer that question. Prior to ...
    ... predict sinkholes? What do ancient ambers reveal about paleochemotaxonomy? ... us understand current global warming? Did trilobites venture into ... above sea level? What does the 27 March 2013 ... you reconstruct snapshots of a catastrophic radial current? What ...
    ... The wild bison roaming Catalina Island are a major attraction ... Island,s most popular destination every year. But managing the number ... endanger the health of the rest of the Island has ... new study by the Catalina Island Conservancy scientists, published in ...
    Cached Biology News:Healthier Happy Meals 2New geology research explores intriguing questions 2New geology research explores intriguing questions 3New geology research explores intriguing questions 4New geology research explores intriguing questions 5New geology research explores intriguing questions 6New geology research explores intriguing questions 7New geology research explores intriguing questions 8New geology research explores intriguing questions 9Study finds Catalina Island Conservancy contraception program effectively manages bison population 2
    Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
    Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
    AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
    Biology Products: